Bayer's Three Clocks: A Courtroom Witness, a Pending FDA Review and a 2031 Ohio Plant
Published on 10/13/2026 at 15:31 | Editorial boerse-global.de
Bayer is currently running three separate tracks at three very different speeds, and conflating them is the easiest way for investors to misread the German group's news flow. One item is already in force, one is a regulatory waypoint rather than a destination, and one is a construction blueprint whose first module will not switch on until 2031.
A witness statement is not a verdict
On October 7, according to media reports, an oncologist testified in a fresh Roundup case that the herbicide was responsible for blood cancers diagnosed in three plaintiffs. The proceeding is being heard in a Missouri court and centres on glyphosate allegations.
That testimony has to be placed where it belongs: as the position of a witness in an ongoing trial. It cannot be equated with a judicial finding that the product caused the illnesses in question. What the report captures is a procedural step, not a completed ruling — a distinction that matters a great deal when weighing Bayer's litigation exposure.
Nor does progress elsewhere in the company answer the claims being argued in Missouri. By the same token, a witness's account says nothing about whether Bayer's pharmaceutical ambitions will succeed. The two strands require separate scorecards.
Should investors sell immediately? Or is it worth buying Bayer?
Finerenon clears an administrative hurdle — nothing more
Bayer's supplemental application for finerenon, marketed as Kerendia, has been accepted for review by the US Food and Drug Administration, the company said. The filing seeks approval for the treatment of adults with chronic kidney disease who do not have diabetes, and rests on data from the Phase III FIND-CKD trial.
The operative word is "accepted." Acceptance of a filing does not mean the additional indication has been granted. Positive trial results underpin the application, but they do not substitute for the agency's decision on the proposed patient population. Bayer has reached a regulatory waypoint; the approval process itself is still open. For shareholders, the review — not an already-completed broadening of the label — is the thing to watch.
Ohio: $2.2 billion, 600 jobs, and a long runway
Roughly two weeks ago, Bayer announced a $2.2 billion investment in a pharmaceutical production site in New Albany, Ohio. The first module is scheduled to come online in 2031, the second in 2034, with around 600 highly qualified positions planned.
Those start-up dates say everything about the character of the project: this is a long-horizon commitment. Unlike the finerenon filing, which concerns an additional use for an existing medicine, the Ohio plan is about manufacturing capacity. An announced site is not a finished build, just as an accepted application is not an approval.
The one item that is already live
Set against both of those forward-looking items is a personnel change that has already taken effect. Dr. Christoph Koenen was named Chief Medical Officer, a move reported about two weeks ago and effective since October 1. He retains his existing responsibility for clinical development and operations in the pharmaceutical division alongside the new role.
So the picture is a live organisational change standing next to plans still working their way through the system. Bayer has named concrete steps in its pharma business — but the decisive next milestones remain the FDA's verdict on finerenon and, in Ohio, execution of the investment as announced.
Ad
Bayer Stock: New Analysis - 13 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
